Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Candel Therapeutics Inc
(NQ:
CADL
)
5.330
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
673
Open
5.330
Bid (Size)
5.150 (10)
Ask (Size)
5.330 (1)
Prev. Close
5.330
Today's Range
5.330 - 5.330
52wk Range
0.7700 - 14.30
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Today 8:00 EST
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
November 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Performance
YTD
+267.59%
+267.59%
1 Month
-17.11%
-17.11%
3 Month
+6.18%
+6.18%
6 Month
-50.78%
-50.78%
1 Year
+479.35%
+479.35%
More News
Read More
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
October 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Looking Into Candel Therapeutics's Recent Short Interest
May 22, 2024
Via
Benzinga
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
October 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Candel Therapeutics
Via
GlobeNewswire
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
August 13, 2024
Via
InvestorPlace
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
July 18, 2024
Via
Benzinga
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 18, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
June 14, 2024
Via
News Direct
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
Via
InvestorPlace
Why BioRestorative Therapies Stock Is Moving Higher Thursday
June 13, 2024
Via
Benzinga
Candel Therapeutics to Join Russell 3000® Index
June 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
June 07, 2024
Via
News Direct
12 Health Care Stocks Moving In Monday's After-Market Session
June 03, 2024
Via
Benzinga
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
June 03, 2024
Via
TheNewswire.com
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
June 03, 2024
Via
News Direct
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
May 30, 2024
From
Candel Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 27, 2024
Via
Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
May 24, 2024
Via
Benzinga
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
May 23, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
May 22, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.